Congress mandates free HIV prevention drugs across all insurance plans
H.R. 5127 — PrEP and PEP are Prevention Act · Filed by Maxine Waters (D-CA) · 35 cosponsors · Introduced Sep 4, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires all major health insurance plans—private insurance, Medicare, Medicaid, CHIP, and federal employee plans—to cover HIV prevention drugs (PrEP and PEP), related lab tests, counseling, and monitoring at no cost to patients. It eliminates copays, deductibles, and prior-authorization delays for these preventive services across all insurance types.
Why we flagged it
The bill's core function is to mandate no-cost coverage of HIV prevention services across all major insurance programs. It is straightforward public health policy with no hidden mechanisms or narrow carve-outs.
What the text implies
- Eliminates prior-authorization (preauth) delays for HIV prevention drugs, which may accelerate access to PrEP/PEP in urgent situations but could reduce insurers' ability to manage formulary costs.
- Applies uniformly across all insurance types (private, Medicare, Medicaid, CHIP, federal employees), creating a national standard that may pressure state Medicaid programs to absorb costs without additional federal funding.
The full analysis lists 5 implications of this text.
Who stands to gain
pharmaceutical manufacturers (PrEP/PEP drug makers); diagnostic testing providers; clinical counseling and monitoring services